NYSE: CRL
Charles River Laboratories International Inc Stock

$158.04-1.36 (-0.85%)
Updated Jul 14, 2025
CRL Price
$158.04
Fair Value Price
N/A
Market Cap
$7.76B
52 Week Low
$91.86
52 Week High
$254.15
P/E
-263.4x
P/B
2.43x
P/S
1.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.02B
Earnings
-$25.29M
Gross Margin
32.4%
Operating Margin
3.66%
Profit Margin
-0.8%
Debt to Equity
1.36
Operating Cash Flow
$776M
Beta
1.24
Next Earnings
Jul 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A

CRL Overview

Charles River Laboratories International, Inc. offers a variety of preclinical and clinical laboratory, gene therapy, and cell therapy services to the Pharmaceutical, Medical Device, and Biotechnology sectors. Charles River was founded in 1947 and is headquartered in Wilmington, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CRL's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Diagnostic & Research

Industry Rating
C
CRL
Ranked
#10 of 43

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$48.28A
$16.31B
$98.53B
View Top Diagnostic & Research Stocks

Be the first to know about important CRL news, forecast changes, insider trades & much more!

CRL News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CRL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CRL is good value based on its book value relative to its share price (2.43x), compared to the US Diagnostics & Research industry average (3.57x)
P/B vs Industry Valuation
CRL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CRL due diligence checks available for Premium users.

Valuation

CRL price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-263.4x
Industry
20.04x
Market
31.22x

CRL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.43x
Industry
3.57x
CRL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CRL's financial health

Profit margin

Revenue
$984.2M
Net Income
$25.5M
Profit Margin
2.6%
CRL's Earnings (EBIT) of $147.28M... subscribe to Premium to read more.
Interest Coverage Financials
CRL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$7.6B
Liabilities
$4.3B
Debt to equity
1.36
CRL's short-term assets ($1.51B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRL's long-term liabilities ($3.29B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CRL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$171.7M
Investing
-$45.5M
Financing
-$105.3M
CRL's operating cash flow ($776.39M)... subscribe to Premium to read more.
Debt Coverage Financials

CRL vs Diagnostic & Research Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CRLC$7.76B-0.85%-263.40x2.43x
MEDPC$9.21B-0.97%23.71x15.51x
GHC$6.17B-0.96%-14.68x-24.59x
EXASC$10.24B+4.60%-9.80x4.27x
QGENA$10.51B+0.31%112.28x3.08x

Charles River Laboratories International Stock FAQ

What is Charles River Laboratories International's quote symbol?

(NYSE: CRL) Charles River Laboratories International trades on the NYSE under the ticker symbol CRL. Charles River Laboratories International stock quotes can also be displayed as NYSE: CRL.

If you're new to stock investing, here's how to buy Charles River Laboratories International stock.

What is the 52 week high and low for Charles River Laboratories International (NYSE: CRL)?

(NYSE: CRL) Charles River Laboratories International's 52-week high was $254.15, and its 52-week low was $91.86. It is currently -37.82% from its 52-week high and 72.04% from its 52-week low.

How much is Charles River Laboratories International stock worth today?

(NYSE: CRL) Charles River Laboratories International currently has 49,115,712 outstanding shares. With Charles River Laboratories International stock trading at $158.04 per share, the total value of Charles River Laboratories International stock (market capitalization) is $7.76B.

Charles River Laboratories International stock was originally listed at a price of $22.00 in Jun 23, 2000. If you had invested in Charles River Laboratories International stock at $22.00, your return over the last 25 years would have been 618.36%, for an annualized return of 8.21% (not including any dividends or dividend reinvestments).

How much is Charles River Laboratories International's stock price per share?

(NYSE: CRL) Charles River Laboratories International stock price per share is $158.04 today (as of Jul 14, 2025).

What is Charles River Laboratories International's Market Cap?

(NYSE: CRL) Charles River Laboratories International's market cap is $7.76B, as of Jul 15, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Charles River Laboratories International's market cap is calculated by multiplying CRL's current stock price of $158.04 by CRL's total outstanding shares of 49,115,712.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.